On August 24, Hims & Hers Health Inc. declined 6.78% in regular trading, trading at $31.0 per share, with turnover of approximately $48.81 million. The decline was driven by Barclays lowering its price target from $39 to $35 while maintaining an Overweight rating, compounded by ongoing pressure from credit card dispute issues.

According to reports, the company was enrolled in Visa's Acquirer Monitoring Program following a surge in credit card disputes in July related to its weight-loss subscription business. Each dispute carries an $8 surcharge, resulting in an estimated bill of nearly $75,000 in September. The company was notified by payment processor Stripe and must bring its dispute rate below 1.5% of transactions for three consecutive months to exit the program. A company spokesperson stated it has seen a relatively small number of disputed charges and has taken steps to address the issue.

The stock had previously recovered from a 12%-plus drop on July 30 triggered by an FTC lawsuit alleging improper data sharing with Meta and Snap, but the latest developments have renewed selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)